|

AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images

RECRUITINGSponsored by Istanbul Training and Research Hospital
Actively Recruiting
SponsorIstanbul Training and Research Hospital
Started2026-05-22
Est. completion2027-05-22
Eligibility
Age0 Years – 100 Years
Healthy vol.Accepted

Summary

This retrospective observational study aims to develop and evaluate a convolutional neural network (CNN)-based artificial intelligence model for risk classification and histopathological subtype prediction of basal cell carcinoma (BCC) using clinical and dermoscopic images. Histopathologically confirmed BCC cases from a dermatology archive will be included. The primary objective is to assess the diagnostic performance of the CNN model in classifying BCC as low-risk or high-risk. Secondary objectives include predicting histopathological subtypes and comparing the model's performance with that of dermatology physicians. Histopathological diagnosis will serve as the reference standard. All archived data will be anonymized before analysis.

Eligibility

Age: 0 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with histopathologically confirmed basal cell carcinoma.
* Cases with a specified histopathological subtype.
* Availability of dermoscopic images with sufficient image quality and resolution for artificial intelligence analysis.

Exclusion Criteria:

* Cases without histopathological confirmation of basal cell carcinoma.
* Cases with unspecified histopathological subtype.
* Images with insufficient quality or resolution for artificial intelligence analysis.
* Cases without available dermoscopic images.

Conditions2

Basal Cell CarcinomaCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.